stockrow
Friday 6 November 2026
Export CDIO’s income statement to Excel — free account
Cardio Diagnostics Holdings, Inc.
CDIO Healthcare Biotechnology
Cardio Diagnostics Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14,800.00, down 57.6% from fiscal 2024.
- Revenue
- +23.8%
- EPS
- +47.4%
- Free cash flow
- +2.59%
Quarter to September 2026, against a year earlier
1.65
0.03
−1.79%
Follow CDIO
Alert me
| Sep '26 From the 10-Q filed 6 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
367.76 | 443.93 | 331.71 | 318.47 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(3.71) | (4.83) | (3.55) | (3.48) | |
P/B ratio |
0.98 | 0.87 | 0.62 | 0.68 | |
Price to Tangible BV |
0.98 | 0.87 | 0.62 | 0.68 | |
EV/Sales |
109.89 | 61.27 | (92.06) | (24.52) | |
EV/EBITDA |
0.00 | 0.00 | 0.25 | 0.06 | |
EV/Operating CF |
(0.29) | (0.16) | 0.26 | 0.06 | |
EV/FCF |
(0.28) | (0.15) | 0.25 | 0.06 | |
Quick Ratio |
15.81 | 15.56 | 14.41 | 8.46 | |
Current Ratio |
17.44 | 17.15 | 15.76 | 9.79 | |
Net Debt/EBITDA |
2.41 | 3.98 | 4.19 | 3.73 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.88 | 0.89 | 0.87 | 0.93 | |
Capex/Depreciation |
0.00 | 0.00 | (0.02) | 0.00 | |
Interest Coverage |
(754.54) | (440.62) | (524.94) | (636.17) | |
Research and Development Expense of Revenue |
0.00% | 3,016.67% | 4,807.41% | 9,552.78% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 24,722.22% | 61,192.59% | 30,877.78% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
677.94% | 451.85% | 914.81% | 666.67% | |
Graham Net Nets |
0.71 | 0.87 | 1.28 | 1.08 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(153.68%) | (133.33%) | (173.33%) | (137.27%) | |
Free Cash Flow Yield |
(105.76%) | (89.86%) | (109.62%) | (124.63%) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
0.00 | (0.45) | (0.55) | (0.78) | |
Capex per Share |
— | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.00 | (0.45) | (0.55) | (0.78) | |
Cash per Share |
0.00 | 1.89 | 2.49 | 2.92 | |
Shareholders Equity per Share |
0.00 | 2.51 | 3.13 | 3.98 | |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.00 | 2.51 | 3.13 | 3.98 | |
Free Cash Flow |
(1.52) | (1.34) | (1.56) | (1.36) | |
Working Capital |
4.10 | 5.80 | 7.25 | 5.32 | |
Capital Expenditures |
— | 0.00 | 0.00 | 0.00 | |
Net Current Asset Value |
3.99 | 5.66 | 7.09 | 5.13 | |
EV/EBIT |
0.00 | 0.00 | 0.23 | 0.06 | |
Capex to Sales |
0.00 | 0.00 | 0.67 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.01 | 0.01 | 0.01 | 0.01 | |
Average Payables |
0.14 | 0.09 | 0.12 | 0.09 | |
Average Assets |
7.44 | 9.16 | 10.92 | 9.19 | |
Average Common Equity |
6.93 | 8.58 | 10.14 | 8.27 |
Columns are period end dates · fundamentals updated 6 Nov 2026